Device Trial Radar · NCT07890740
Continuous Glucose Monitoring and Dietary Self-Management in Adults in Namwon
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
860
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Sep 2027
Study completion Sep 2028
Sponsor
- Lead sponsor
- Ji-Yeob ChoiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Korea Health Industry Development Institute
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test whether adding a continuous glucose monitoring (CGM) device, which shows personal glucose patterns, improves dietary self-management over the first 6 weeks. Both groups receive the same digital health program, standardized education, and support for setting behavioral goals. It will include 860 residents of Namwon, Republic of Korea, aged 40 years or older who have elevated fasting glucose or documented type 2 diabetes diagnosis or treatment. After screening, participants will be assigned by chance to one of two groups of 430. Assignment is preferably on the first screening visit but may occur later. The actual assignment date is Day 0. The device group will use one CGM sensor for approximately 10 days after assignment. The wait-list control group will receive the same education and behavioral goal-setting support during the first 6 weeks, without a CGM device. Researchers will compare dietary self-management scores at week 6, before the control group receives a sensor. After the week 6 assessment and data lock, the control group will also be offered a sensor so that all eligible randomized participants have an opportunity to use the device. This later offer is not the main intervention comparison. Week 12 assessments provide exploratory follow-up after both groups have been offered a device. Researchers will also assess application use, body weight, waist circumference, blood pressure, and safety. The research team will not change medicines based on sensor readings, and usual medical care will continue.
Conditions
- Prediabetes
- Dietary Self-Management
- Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring With Application-Based BiofeedbackDevice
One Dexcom G7 sensor is worn for approximately 10 days, with personal glucose patterns displayed through PASTA as biofeedback for lifestyle self-management. The device group starts on the actual randomization date (Day 0) or within 10 business days. The wait-list control group receives no device during the first 6 weeks and is offered the sensor after the week 6 assessment and data lock, on that day or within 7 business days, to provide access for all eligible participants. Both groups receive the same standardized education and behavioral goal setting during the first 6 weeks. The primary contrast is the incremental device effect during that period. Sensor placement, connection, and safety instructions accompany actual use. Research staff do not adjust medicines based on readings.
Common Standardized Education and Behavioral Goal SettingBehavioral
Both randomized groups receive the same standardized education and behavioral goal-setting support during the first 6 weeks, regardless of whether a CGM device has been provided. Education covers interpretation of glucose patterns, relationships of meals, activity and sleep with glucose responses, differences in responses to foods, and safe behavioral goals. Safety guidance includes not changing medicines, insulin or food intake solely on the basis of sensor readings. This is a common component, not the randomized difference; it is not postponed until sensor provision in the wait-list control group. Instructions for actual sensor placement, application connection, and device safety are distinguished from this common education.
Common Digital Health Program and Basic Health CounselingBehavioral
Both randomized groups receive the same background program beginning at the first screening visit, which may precede randomization: PASTA application guidance, the commercially available AI Diet dietary assessment and feedback provided through Kakao Healthcare's PASTA application, using the existing 10 dietary categories and risk-stage table without modification, CancerFree prevention information, assistance with digital skills, and basic health counseling. Standardized education and behavioral goal setting are also common to both groups during the first 6 weeks. Personal glucose-linked functions become available only when a sensor is provided; actual placement, connection, and device safety instructions accompany device use. The common background program has no separate untreated comparator in this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dietary Self-Management Score at Week 6Time frame: Week 6 after the actual randomization date (Day 0); assessment window: Days 35-49.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Namwon City Hall
Namwon, Jeollabuk-do, South Korea
Namwon Medical Center
Namwon, Jeollabuk-do, South Korea
Namwon Public Health Center
Namwon, Jeollabuk-do, South Korea
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.